Phase II Study of Pentostatin in Advanced T-Cell Lymphoid Malignancies: Update of an M. D. Anderson Cancer Center Series

Cancer

Volumn 100, Issue 2, 2004, Pages 342-349

  Tsimberidou, Apostolia Maria ^a   Giles, Francis ^a   Duvic, Madeleine ^a   Fayad, Luis ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenosine; Deaminase; Inhibitor; Lymphomas; T cells

Indexed keywords

ALLOPURINOL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETANERCEPT; ETOPOSIDE; FLUDARABINE; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; PENTOSTATIN; PREDNISONE; PSORALEN; RETINOID; VALACICLOVIR; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; HUMAN; MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEZARY SYNDROME; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKEMIA, T-CELL; LYMPHOMA, T-CELL; MIDDLE AGED; PENTOSTATIN; TREATMENT OUTCOME;

EID: 0346724524     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11899     Document Type: Article

References (36)

1. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000;96:2981-2986.
2. Ackeret C, Lluss HJ, Hitzig WH. Hereditary severe combined immunodeficiency and adenosine deaminase deficiency. Pediatr Res. 1976;10:67-70.
3. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13:974-982.
4. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 2003;17:45-51.
5. Grever MR, Bisaccia E, Scarborough DA, Metz EN, Neidhart JA. An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood. 1983;61:279-282.
6. Dearden C, Matutes E, Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer. 1991;64:903-906.
7. Cummings FJ, Kim K, Neiman RS, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol. 1991;9:565-571.
8. Greiner D, Olsen EA, Petroni G. Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 1997;36:950-955.
9. Monfardini S, Sorio R, Cavalli F, et al. Pentostatin (2′ -deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: Phase II study of the EORTC Early Clinical Trials Group. Oncology. 1996;53:163-168.
10. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994;12:2588-2593.
11. Willemze R, Meijer CJ. EORTC classification for primary cutaneous lymphomas: a comparison with the R.E.A.L. classification and the proposed WHO classification. Ann Oncol. 2000;11 Suppl 1:11-15.
12. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
13. Connors JM, Hsi ED, Foss FM. Lymphoma of the skin. In: American Society of Hematology. Education program book. Philadelphia: American Society of Hematology, 2002:263-382.
14. Abel EA, Wood GS, Hoppe RT. Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment. CA Cancer J Clin. 1993;43:93-115.
15. Kashani-Sabet M, McMillan A, Zackheim HS. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2001;45:700-706.
16. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood. 1996;88:2385-2409.
17. Bunn PA Jr., Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med. 1994;121:592-602.
18. Bunn PA Jr. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy? Arch Dermatol. 1995;131:603-605.
19. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood. 1998;92:1150-1159.
20. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J Am Acad Dermatol. 1999;40:914-924.
21. Vonderheid EC, Zhang Q, Lessin SR, et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol. 1998;38:207-220.
22. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med. 1987;316:297-303.
23. National Cancer Institute Cancer Therapy Evaluation Program. The revised common toxicity criteria, version 2.0. Available from URL: http://ctep.cancer.gov/forms/ctcaev2to3.pdf [accessed 11 November 2003].
24. Dixon DO, McLaughlin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987;5:1670-1672.
25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
26. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol. 1999;17:3117-3121.
27. Ho AD, Suciu S, Stryckmans P, et al. Pentostatin in T-cell malignancies - a Phase II trial of the EORTC. Leukemia Cooperative Group. Ann Oncol. 1999;10:1493-1498.
28. Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol. 1992;10:1907-1913.
29. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology (Huntingt). 2000;14(6 Suppl 2):37-40.
30. Lombardi A, Caniglia M, Longo D, et al. Treatment of Langerhans cell histiocytosis with 2′-deoxycoformycin (2′-DCF). Hematol J. 2002;3:118-119.
31. + large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin. Hematol Oncol. 2002;20:87-93.
32. Kurzrock R. Therapy of T cell lymphomas with pentostatin. Ann N Y Acad Sci. 2001;941:200-205.
33. + lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia. 1997;11:42-47.
34. Todd SA, Morris TC, Alexander HD. Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin. Leuk Lymphoma. 2002;43:1343-1344.
35. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T-cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002;3:193-215.
36. Au WY, Liang R. Peripheral T-cell lymphoma. Curr Oncol Rep. 2002;4:434-442.